The trilingual magazine of the city of Barcelona, Barcelona Metropolis, dedicates its leading article and an extensive report to the biomedicine conducted in Barcelona. Various articles in this edition address topics related to this discipline, ranging from biomedicine as a business model and associated research fields, such as biomedical chemistry or big data, to key institutions such as the Catalan Institution for Research and Advanced Studies (ICREA).
IRB Barcelona is well represented in the magazine, with references and statements by Joan Guinovart, director of the institute, Patrick Aloy, Eduard Batlle, Natàlia Carulla, Ernest Giralt, Modesto Orozco, and Xavier Salvatella,...
Cristina Sáez, a journalist specialised in science, wrote this long article on Alzheimer’s disease, published in The Magazine of La Vanguardia. The article includes statements, among others, of various scientists specialised in this disease, including Natàlia Carulla, Ramón y Cajal associate researcher in the Peptide and Protein Laboratory, and Patrick Aloy, ICREA researcher and group leader of the Structural Bioinformatics and Network Biology Laboratory, at IRB Barcelona.
Read the article in The Magazine (in Spanish)
The European project «ECMED» (acronym of Extracellular Matrix in Epileptogenesis) is aimed to design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy.
The project, which has a duration of three years and a budget of € 3.5 million, is co-funded by the European Union within the Horizon 2020 research and innovation framework program through a Marie Sklodowska-Curie grant.
Radio 5 (RNE) has broadcasted a report on a molecule developed by IRB Barcelona capable of crossing the barrier that protects the brain and transporting drugs inside. The breakthrough made by the Peptide and Protein Laboratory was recently published in Angewandte Chemie.
Roger Prades, first author of the article and who did his PhD in this lab, and Benjamí Oller, a PhD student in the same lab, explain how this shuttle works. The molecule opens the door to the development of new drugs for diseases that affect the central nervous system, in addition to giving a new opportunity to drugs previously discarded because they are unable reach the brain unaided.
Gate2Brain is one of the projects to receive research funding from the Obra Social “la Caixa”
The results of the IRB Barcelona project could have applications in various neurodegenerative diseases
Of the 221 projects presented, only 26 have been awarded funding
An article in “El Punt Avui” newspaper mentions the most recent advances made by the Peptides and Proteins Laboratory at IRB Barcelona, headed by Ernest Giralt, also full professor at the UB. This lab has identified several substances capable of transporting drugs across the barrier that protects the brain from infections. The article includes statements made by Giralt and explains the projects underway in his lab to find treatments for various neurological diseases and tumours.
Read the article in El Punt Avui (in Catalan)
“El País” has included an article about Spark, the project started by the public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off. IRB Barcelona, CRG, the University of the Basque Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project. The article includes statements by Teresa Tarragó, researcher at IRB Barcelona and co-founder of Iproteos, and Miquel Bernardo, director of the Schizophrenia Unit at the Hospital Clínic and main researcher of the Mental Health network CIBERSAM.
Read the article in El País (in Spanish)
TV3 News has broadcasted a report on a shuttle molecule capable of crossing the barrier that protects the brain from infections and of transporting therapeutic molecules into this organ —a development patented by members of the Peptides and Proteins Laboratory at IRB Barcelona, headed by Ernest Giralt, also full professor at the UB. In the report, Giralt explains how this shuttle works. His lab is already working on the applications of this shuttle in three projects to treat various diseases that affect the brain.
Watch the video on...
Radio 5 (RNE) has reported on the “Spark” project, launched by the public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off. IRB Barcelona, CRG, the University of the Basque Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project. The program includes statements by Javier Meana, researcher at the University of the Basque Country, and Teresa Tarragó, researcher at IRB Barcelona and co-founder of Iproteos.
Listen to the news on Radio 5 (04:30 minutes, in Spanish)
Radio Euskadi interviews Meritxell Teixidó, associate researcher in the Peptide and Protein Laboratory at IRB Barcelona, about the development of a shuttle peptide capable of crossing the blood-brain barrier and carrying therapeutic molecules in to this organ to treat diseases of the central nervous system. In the interview, Teixidó talks about how the shuttle works and about its potential therapeutic applications.
Listen to the interview on Radio Euskadi (10:36 minutes, in Spanish)